Skip to main content
MIRM logo

Mirum Pharmaceuticals, Inc. (MIRM) Stock: Price, Forecast & Analyst Target

Mirum Pharmaceuticals, Inc. (MIRM) — MoonshotScore 14/100 (Weak band), calculated Nov 18, 2026. Price $96.13 (+0.65%), as of the Nov 20, 2026 trading session; market cap $6.28B.

Educational signal · not a buy or sell recommendation · How to read this

$96.13 +$0.62 (+0.65%) Market Cap $6.28B

Mirum Pharmaceuticals, Inc. · MIRM · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Mirum Pharmaceuticals develops therapies for rare, inherited liver diseases where few alternatives exist. The company has one commercial drug generating revenue and a second in development, but both remain in early regulatory and clinical stages. Success or failure depends almost entirely on FDA decisions and clinical trial outcomes, not market share or operational efficiency.

Price as of Nov 20, 2026

Key Statistics

14 of 100

MoonshotScore v2 · Mirum Pharmaceuticals (MIRM)

Weak
Business Quality Thin (35)
Financial Safety Strained (36)
Valuation Full (46)
Growth Durability Fading (37)
Momentum Rising (74)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Strong price action running well ahead of the business — weak quality underneath; a move to treat with suspicion, not chase. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Fading; Momentum: Rising.

  • EPS beat 0 of the last 4 reports
  • Altman Z -0.51 · Piotroski F 3

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MIRM (58 recorded, newest six shown)
RecordedScoreBand
15Weak
15Weak
15Weak
14Weak
14Weak
14Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$96.13
Change on the day+0.65%
52-week range$63.23–$130.00
Market capitalisation$6.28B—
Price / earnings (trailing)-181.90
Shares traded on the day1.06M
Beta (volatility vs the S&P 500)0.74

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $65, high $126, latest $96. $126 $65 high $126 Oct 17, 2025 Nov 20, 2026 · $96 $74Oct 17, 2025$73Oct 31, 2025$71Nov 14, 2025$73Nov 28, 2025$65Dec 12, 2025$79Dec 26, 2025$87Jan 9, 2026$94Jan 23, 2026$100Feb 6, 2026$105Feb 20, 2026$86Mar 6, 2026$89Mar 20, 2026$94Apr 2, 2026$98Apr 17, 2026$97May 1, 2026$102May 15, 2026$102May 29, 2026$99Jun 12, 2026$124Jun 26, 2026$122Jul 10, 2026$113Jul 24, 2026$101Aug 7, 2026$96Aug 21, 2026$101Sep 4, 2026$92Sep 18, 2026$83Oct 2, 2026$80Oct 16, 2026$85Oct 30, 2026$94Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Mirum Pharmaceuticals (MIRM): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Weak
Financial Safety Weak
Valuation Neutral
Growth Durability Weak
Momentum Moderate

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
ROE Negative
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Mirum Pharmaceuticals (MIRM), and what does it report?

Short answer · as of

Mirum is a biopharmaceutical firm with a single product on the market—LIVMARLI, an oral treatment for progressive familial intrahepatic cholestasis and related cholestatic liver diseases.

The company sells this drug while simultaneously conducting trials for bile acid modulators in pregnancy-related and autoimmune liver conditions. Revenue comes from LIVMARLI sales; costs are almost entirely research and development staff trying to bring the second drug to the market.

The reported numbers reflect a company at an inflection point. Quarterly revenue has grown steadily since the drug launched, but operating expenses dwarf sales because the second program demands a full research workforce. The income statement shows deepening losses on a generally expanding revenue base, which is typical for early commercialization of a specialty rare-disease therapy.

2 · Latest results

What do the latest results show for Mirum Pharmaceuticals (MIRM)?

The most recent quarter showed revenue growth, with gross margins above realistic levels for a specialty pharma despite fixed manufacturing costs. Operating losses widened, however, as research intensity increased in preparation for regulatory submissions. Cash flow deteriorated sharply in the same period, driven both by higher operating burn and by the timing of cash receipts and payables—a temporary pattern, but one that compounds when runway is already finite.

Analyst revisions have been volatile, suggesting uncertainty about trial timelines and commercial ramp. The most recent earnings report surprised to the downside on per-share loss, though revenue itself met guidance, indicating that cost controls slipped rather than sales momentum failed.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$133M$3M$0.05 (diluted)
Q4 FY2025$149M-$6M-$0.11 (diluted)
Q1 FY2026$160M-$790M-$13.43 (diluted)
Q2 FY2026$176M-$67M-$1.06 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Mirum Pharmaceuticals (MIRM)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Mirum holds enough cash and short-term investments to fund operations for roughly another year and a half, a runway that extends into the period when regulatory decisions on the second drug become likely. The balance sheet shows strong liquidity ratios, meaning the company can cover near-term obligations easily. Debt is modest relative to cash, and the company carries no catastrophic lease or pension obligations.

The central risk is not balance-sheet fragility but clinical and regulatory outcomes. If trials succeed and the FDA approves, the company moves to profitability quickly under analyst models. If trials stall or regulators demand more data, the company exhausts cash before generating enough revenue to sustain itself. Insiders have not purchased shares in the past half-year despite what would normally be attractive valuations after a recent price decline, a signal that insiders expect uncertainty to persist.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -0.51 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Mirum Pharmaceuticals (MIRM)?

Short answer · as of

Current published price targets run low $130.00 · high $202.00 · consensus $154.82 · median $146.00 against a quoted price of $96.13 (as of Nov 20, 2026).

The next material event is the FDA's response to pending submissions for LIVMARLI in additional indications and for Volixibat. Approval dates should be disclosed within the coming quarters. Commercial scaling, if approved, will move from aspirational to observable in pricing discussions and insurance negotiation announcements.

Analyst estimates project profitability within several years, conditional on both drugs reaching the market and capturing expected pricing. Each trial readout, regulatory decision, and quarterly revenue update will either validate or undermine these assumptions. The company also faces the question of whether cash on hand suffices to reach break-even, or whether a financing round becomes necessary before then.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Mirum Pharmaceuticals compare with its peers?

Short answer

Mirum Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Rare-disease biotech operates on a fundamentally different model than broad-market pharmaceutical companies. Success is not about market share or competitive pricing; it is about regulatory approval and patient identification in a small population. Mirum has no generic or biosimilar competitors and faces no price pressure from volume alone—the limiting constraint is FDA acceptance and insurance coverage.

Compared to other rare-disease companies at similar clinical and commercial stages, Mirum's cash runway and burn rate are within normal bounds. Unlike early-stage pure biotech firms without approved drugs, Mirum has proof of commercial demand through LIVMARLI sales. Unlike large pharmaceutical corporations, it carries no legacy costs, no portfolio diversification, and no defensive marketing burden. The difference is not quality but structure: Mirum succeeds or fails on a single therapeutic area and a handful of clinical programs.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.89 Nov 20, 2026$7.38B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$308.89 Nov 20, 2026$9.15B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$91.35 Nov 20, 2026$10.4B95 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$63.62 Nov 20, 2026$6.96B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$63.34 Nov 20, 2026$9.57B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$121.40 Nov 20, 2026$7.92B88 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$39.91 Nov 20, 2026$4.37B84 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$17.58 Nov 20, 2026$5.04B83 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Named competitor$286.85 Nov 20, 2026$5.74B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$95.81 Nov 20, 2026$6.50B67 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$13.61 Nov 20, 2026$4.78B67 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$119.52 Nov 20, 2026$5.04B66 5-pillar Nov 18, 2026
Mirum Pharmaceuticals (MIRM) — this page$96.13$6.28B14

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$130.00 – $202.00
Consensus target
$154.82
Median target
$146.00

Consensus record · Captured .

Measured against a quoted price of $96.13 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 11, 2026

Transactions
59
Identified insiders
11
Purchases
0
Sales
23
Other transactions
36

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MIRM in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MIRM in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Mirum Pharmaceuticals (MIRM)?

Read these with our analysis →

Mirum Pharmaceuticals Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

What is LIVMARLI and when did it launch?

LIVMARLI is an oral therapy for inherited cholestatic liver disease, the only approved drug in its class for progressive familial intrahepatic cholestasis. The company has been commercializing it and expanding clinical trials to additional disease conditions where the same mechanism may apply.

How much longer can the company operate without profitability?

Mirum's current cash and investments support operations for roughly another year and a half if burn rates remain stable. This window aligns with expected regulatory and trial readout timelines, but does not provide margin for delays. If trials slow or FDA decisions take longer than anticipated, the company may require additional financing.

Why are insiders selling shares?

Insiders have executed restricted stock vesting and have sold shares in the open market, a pattern consistent with tax-withholding and diversification rather than distress sales. However, the absence of any insider purchases in the past half-year suggests no conviction that the current valuation offers sufficient margin of safety to warrant personal investment.

What is the single biggest uncertainty for this stock?

FDA approval decisions and clinical trial outcomes for both LIVMARLI extensions and Volixibat will determine whether Mirum reaches sustainable profitability or exhausts cash and must dilute shareholders. Investors have no way to predict or control these outcomes; they can only wait for reports and trial readouts. The company's success or failure is binary in a way that operational improvements cannot remedy.

What is the MIRM stock price today?

The last price recorded for Mirum Pharmaceuticals, Inc. (MIRM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MIRM price target?

The analyst consensus price target for Mirum Pharmaceuticals, Inc. (MIRM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 22 figures on this page — 19 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Legal name; Sector / industry (provider taxonomy)
  • 1. What is Mirum Pharmaceuticals (MIRM), and what does it report?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Employees
  • 2. What do the latest results show for Mirum Pharmaceuticals (MIRM)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Analyst revenue and earnings estimates (average)
  • 3. What are the financial strengths and risks for Mirum Pharmaceuticals (MIRM)?: Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Insider transactions, last 180 days; Trailing twelve-month ratio set
  • 4. What should you watch next at Mirum Pharmaceuticals (MIRM)?: Next earnings report; Analyst revenue and earnings estimates (average); Recent SEC filings; Analyst actions, most recent per firm
  • 5. How does Mirum Pharmaceuticals compare with its peers?: Business description; Sector / industry (provider taxonomy); Institutional ownership (13F); Analyst actions, most recent per firm
  • FAQ: What is LIVMARLI and when did it launch?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: How much longer can the company operate without profitability?: Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Operating cash flow by quarter (USD millions)
  • FAQ: Why are insiders selling shares?: Insider transactions, last 180 days; Trailing twelve-month ratio set; Largest 5 institutional holders
  • FAQ: What is the single biggest uncertainty for this stock?: Analyst revenue and earnings estimates (average); Recent SEC filings; Cash runway cross-check (ours)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold MIRM

Funds in our ETF coverage that list MIRM among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
State Street SPDR S&P Biotech ETF (XBI)1.41%
Federated Hermes MDT Small Cap Core ETF (FSCC)1.31%